Inventor · disambiguated record
Bianka Prinz
Also filed as: PRINZ BIANKA · PRINZ BIANKA DOMINIQUE
59 granted patents·65 pending applications·177 citations·filing 2001–2025
98Inventor score
Files withDRAGONFLY THERAPEUTICS INC45MERCK SHARP & DOHME9TUSK THERAPEUTICS LTD9UNIV TEXAS9Black Belt Therapeutics Ltd8
Top patents by PatentIndex Score
124 records- 0197US11939384B1Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·9 cites·16 claims
- 0297US10752691B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·12 cites·29 claims
- 0396US11884733B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Jan 30, 2024·10 cites·14 claims
- 0496US10745485B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 18, 2020·11 cites·29 claims
- 0596US10738125B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 11, 2020·11 cites·25 claims
- 0696US9738720B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2016·Granted Aug 22, 2017·10 cites·30 claims
- 0794US12129300B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·8 claims
- 0894US9555112B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2015·Granted Jan 31, 2017·13 cites·42 claims
- 0993US10676536B2Anti-coagulation factor XI antibodiesMERCK SHARP & DOHME·Filed 2017·Granted Jun 9, 2020·6 cites·18 claims
- 1092US8067339B2Surface display of whole antibodies in eukaryotesPRINZ BIANKA·Filed 2009·Granted Nov 29, 2011·18 cites·11 claims
- 1191US11884732B2Proteins binding HER2, NKG2D and CD16DRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Jan 30, 2024·6 cites·15 claims
- 1291US11312783B2Antibody molecules to CD73 and uses thereofNOVARTIS AG·Filed 2018·Granted Apr 26, 2022·10 cites·26 claims
- 1390US8715963B2Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastorisSETHURAMAN NATARAJAN·Filed 2011·Granted May 6, 2014·16 cites·18 claims
- 1489US10053515B2Anti-coagulation factor XI antibodiesMERCK SHARP & DOHME·Filed 2017·Granted Aug 21, 2018·6 cites·18 claims
- 1589US2025066489A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1688US11976128B2Human PD-L2 antibodies and methods of use thereforUNIV TEXAS·Filed 2019·Granted May 7, 2024·2 cites·21 claims
- 1788US11525002B2Human PD-L1 antibodies and methods of use thereforUNIV TEXAS·Filed 2018·Granted Dec 13, 2022·3 cites·20 claims
- 1888US10793637B2Antibodies that bind CD39 and uses thereofSURFACE ONCOLOGY INC·Filed 2020·Granted Oct 6, 2020·2 cites·20 claims
- 1987US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 2087US12264200B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 2186US12428489B2Human PD-L2 antibodies and methods of use thereforUNIV TEXAS·Filed 2024·Granted Sep 30, 2025·0 cites·10 claims
- 2286US11214619B2Anti-CD112R compositions and methodsSURFACE ONCOLOGY INC·Filed 2019·Granted Jan 4, 2022·4 cites·19 claims
- 2386US2025019444A1Antibody variable domains targeting the nkg2d receptorDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2485US11787866B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 17, 2023·1 cites·11 claims
- 2585US11697688B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jul 11, 2023·1 cites·26 claims
- 2685US11479615B2Anti-coagulation factor XI antibodiesMERCK SHARP & DOHME·Filed 2020·Granted Oct 25, 2022·1 cites·17 claims
- 2785US10738128B2Antibodies that bind CD39 and uses thereofSURFACE ONCOLOGY INC·Filed 2019·Granted Aug 11, 2020·2 cites·19 claims
- 2884US12275800B2Anti-coagulation factor XI antibodiesMERCK SHARP & DOHME LLC·Filed 2023·Granted Apr 15, 2025·0 cites·18 claims
- 2984US12162941B2Anti-CD112R compositions and methodsSURFACE ONCOLOGY LLC·Filed 2021·Granted Dec 10, 2024·1 cites·19 claims
- 3084US11661460B2Anti-coagulation factor XI antibodiesMERCK SHARP & DOHME LLC·Filed 2020·Granted May 30, 2023·1 cites·67 claims
- 3183US11332524B2Anti-IL-27 antibodies and uses thereofSURFACE ONCOLOGY INC·Filed 2019·Granted May 17, 2022·2 cites·19 claims
- 3282US12325747B2Human PD-L1 antibodies and methods of use thereforUNIV TEXAS·Filed 2022·Granted Jun 10, 2025·0 cites·11 claims
- 3382US9260712B2Surface display of whole antibodies in eukaryotesPRINZ BIANKA·Filed 2011·Granted Feb 16, 2016·3 cites·18 claims
- 3482US2023265197A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3581US2025059282A1Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use thereforUNIV TEXAS·Filed 2024·Application pending·0 cites
- 3680US2025129167A1Dual specificity antibodies to pd-l1 and pd-l2 and methods of use thereforUNIV TEXAS·Filed 2024·Application pending·0 cites
- 3780US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3880US2025320296A1Human pd-l1 antibodies and methods of use thereforUNIV TEXAS·Filed 2025·Application pending·0 cites
- 3979US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 4079US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 4179US11655303B2Anti-CD39 antibody compositions and methodsSURFACE ONCOLOGY INC·Filed 2020·Granted May 23, 2023·1 cites·19 claims
- 4279US2025051449A1Anti-CD112R Compositions and MethodsSURFACE ONCOLOGY LLC·Filed 2024·Application pending·0 cites
- 4377US12084651B2Surface display of whole antibodies in eukaryotesMERCK SHARP & DOHME LLC·Filed 2021·Granted Sep 10, 2024·0 cites·11 claims
- 4477US10584179B2Anti-coagulation factor XI antibodiesMERCK SHARP & DOHME·Filed 2018·Granted Mar 10, 2020·1 cites·16 claims
- 4576US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 4676US11401339B2Anti-TIGIT antibodiesSEAGEN INC·Filed 2019·Granted Aug 2, 2022·1 cites·122 claims
- 4776US11279758B2Anti-CD112R compositions and methodsSURFACE ONCOLOGY INC·Filed 2019·Granted Mar 22, 2022·1 cites·22 claims
- 4876US11236173B2CD38 antibodyBlack Belt Therapeutics Ltd·Filed 2018·Granted Feb 1, 2022·1 cites·17 claims
- 4976US2023391877A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 5076US2024400676A1Anti-cd19 antibodies and uses therofMILLENNIUM PHARM INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 124 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Bianka Prinz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →